REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 18-000527
    Sponsor Protocol Number: 18-000527

About this study

The purpose of this observational study is to describe the safety and effectiveness of regorafenib in patients with uHCC under real world practice conditions.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Patients with confirmed diagnosis of unresectable HCC
  • Physician-initiated decision to treat with regorafenib (prior to study enrollment)
  • Signed informed consent form
  • Male or female patients, age ≥18 years

Exclusion Criteria: 

  • Participation in an investigational program with interventions outside of routine clinical Practice
  • Past treatment with regorafenib

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Open for enrollment

Contact information:

Hamdi Ali M.D.

Ali.Hamdi@mayo.edu

.
CLS-20417925

Mayo Clinic Footer